JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25 August 2023 and which was later reported by the researchers to have higher transmissibility and immune escape ability, has now been designated a variant of interest (VOIs) by WHO.

In the last few weeks, JN.1 cases have been reported in many countries. Its prevalence is rapidly increasing globally. In view of rapidly increasing spread, WHO has classified JN.1 as a separate variant of interest (VOI).

As per initial risk evaluation by WHO, the additional public health risk posed by JN.1 sub-variant is low at the global level.

Notwithstanding higher infection rate and possibility of immunity evasion, current evidence does not suggest that the disease severity could be higher compared to other circulating variants.

***

References:

  1. WHO.  Tracking SARS-CoV-2 variants – Currently circulating variants of interest (VOIs) (as of 18 December 2023). Available at https://www.who.int/activities/tracking-SARS-CoV-2-variants
  2. WHO. JN.1 Initial Risk Evaluation 18 December 2023. Available at https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3 

***

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

Pandemic Potential of Human Metapneumovirus (hMPV) Outbreaks 

There are reports of outbreaks of Human Metapneumovirus (hMPV)...

Intermittent Fasting or Time-Restricted Feeding (TRF) Has Significant Negative Effects on Hormones

Intermittent fasting has a wide range of effects on...

Types of COVID-19 Vaccines in Vogue: Could There be Something Amiss?

In the practice of medicine, one generally prefers time...

The Fireworks Galaxy, NGC 6946: What Make this Galaxy so Special?

NASA recently released the spectacular bright image of the...

Enhancing Drug Efficiency by Correcting 3D Orientation of Molecules

Researchers have discovered a way to design efficient medicines...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.